Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models
Dato-DXd is active in breast cancer models. Dato-DXd has TROP2-dependent and -independent mediators of activity; however, high TROP2 expression enhances Dato-DXd antitumor activity.
Authors
- Erkan Yuca
- Takanori Maejima (ORCID: https://orcid.org/0000-0003-1295-6504)
- Yasmeen Q. Rizvi (ORCID: https://orcid.org/0009-0000-2719-4093)
- Tsuyoshi Karibe
- Senthil Damodaran (ORCID: https://orcid.org/0000-0002-2470-0891)
- Ximing Tang (ORCID: https://orcid.org/0000-0001-6534-6852)
- Kurt W. Evans (ORCID: https://orcid.org/0009-0008-6823-6809)
- Bailiang Wang
- Argun Akçakanat (ORCID: https://orcid.org/0000-0002-4012-9840)
- Lauren A. Byers (ORCID: https://orcid.org/0000-0002-0780-2677)
- Maria Gabriela Raso (ORCID: https://orcid.org/0000-0003-2105-5556)
- Funda Meric‐Bernstam (ORCID: https://orcid.org/0000-0001-6816-6072)
- Xiaofeng Zheng
- Daisuke Okajima
- Ming Zhao
- Debu Tripathy (ORCID: https://orcid.org/0000-0002-5711-2404)
- Stephen M. Scott
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Daiichi Sankyo (Germany) (DE)
- Daiichi-Sankyo (Japan) (JP)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1948
- Citations
- 15
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.24
Funders
- METAvivor
- Daiichi-Sankyo
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- Daiichi Sankyo Company
- National Cancer Institute
- Moonshot Research and Development Program
- Daiichi Sankyo Europe
- Cancer Moonshot